GnRH receptors and actions in the control of reproductive function.
The hypothalamic control of reproductive function is expressed through the receptor-mediated actions of GnRH on the pituitary gonadotroph. GnRH receptors in the pituitary gland exhibit prominent variations in number during the ovarian cycle and after changes in steroid feedback, and are modulated by the rate of GnRH secretion from the hypothalamus. In cultured pituitary cells, GnRH receptors undergo down-regulation during exposure to GnRH agonists, followed by a subsequent elevation of sites that is dependent on protein synthesis. GnRH antagonists do not cause receptor down-regulation, but high-affinity antagonist analogs bind for extended periods to cause receptor occlusion and prolonged inhibition of GnRH action. Analysis of the rat pituitary GnRH receptor by photoaffinity labeling reveals two binding subunits of mol. wt 53,000 and 42,000. The receptor-activated processes leading to gonadotropin secretion are highly calcium-dependent, and are initiated by rapid phospholipid hydrolysis with production of arachidonic acid metabolites, diacylglycerol, and inositol phosphates. The role of protein kinase C in gonadotropin secretion is indicated by the ability of phorbol esters and synthetic diacylglycerols to stimulate LH release, the inhibition of protein kinase C and LH release by retinal, and the redistribution of protein kinase C between cytosol and membrane fractions during stimulation of pituitary gonadotrophs by GnRH. It is likely that the effects of arachidonate metabolites are integrated with those of calcium-calmodulin and calcium, phospholipid-dependent protein kinases during the immediate and sustained phases of GnRH-induced gonadotropin secretion.
D000818:Animals; D000001:Calcimycin / Q000494:pharmacology; D002499:Centrifugation, Density Gradient; D003513:Cycloheximide / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004591:Electrophoresis, Polyacrylamide Gel; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000378:metabolism; D006801:Humans; D007031:Hypothalamus / Q000502:physiology*; D007295:Inositol Phosphates / Q000096:biosynthesis; D007986:Luteinizing Hormone / Q000378:metabolism; D008854:Microscopy, Electron; D008970:Molecular Weight; D010703:Phorbol Esters / Q000494:pharmacology; D010902:Pituitary Gland / Q000502:physiology; D011335:Proadifen / Q000494:pharmacology; D011493:Protein Kinase C / Q000378:metabolism; D011956:Receptors, Cell Surface / Q000502:physiology*; D011966:Receptors, LHRH; D012098:Reproduction; D013997:Time Factors
D007295:Inositol Phosphates; D010703:Phorbol Esters; D011956:Receptors, Cell Surface; D011966:Receptors, LHRH; D007987:Gonadotropin-Releasing Hormone; D000001:Calcimycin; C010661:surfagon; D007986:Luteinizing Hormone; D003513:Cycloheximide; D011335:Proadifen; D011493:Protein Kinase C